Wednesday, February 12, 2014

LI MD's techniques pale in contrast to

the hospice patients who are imbibing aspirin 

and metformin in last efforts to remain alive on this earth, having tried other treatments that have FAILED!!! and are costly.

 

ASPIRIN AND METFORM, FOR BOOBS AND DICKS WHO BELIEVE THAT THERE IS REASON TO TRY SAME. SEE BELOW.

YOU DON'T THINK ANY BETTER BECAUSE YOU ARE AN MD?

 

Aspirin may lower ovarian cancer risk, research shows

Originally published: February 11, 2014 8:13 PM
Updated: February 11, 2014 9:20 PM
By DELTHIA RICKS  delthia.ricks@newsday.com
Women who take aspirin daily may reduce their
Women who take aspirin daily may reduce their risk of ovarian cancer by 20 percent, report a team of medical scientists who reviewed reams of data pooled from 12 large studies. (Credit: Photos.com)
Women who take aspirin daily may reduce their risk of ovarian cancer by 20 percent, report a team of medical scientists who reviewed reams of data pooled from 12 large studies.
The research, reported in the current issue of the Journal of the National Cancer Institute, was conducted by institute scientists and adds credence to a provocative notion: The old medicine cabinet standby may possess potent anti-cancer properties.
"Our study suggests that aspirin regimens -- proven to protect against heart attack -- may reduce the risk of ovarian cancer as well," said Dr. Britton Trabert of the NCI's cancer epidemiology and genetics division.
BLOG: The Daily Apple | PHOTOS: Dropping LBs
DATA: Explore hospital rankings | Compare hospital charges | Uninsured people in NY | Compare hospital infection data
WEIGH IN: Ask your fitness questions
Dr. Vincent Yang, chairman of medicine at Stony Brook University Hospital, said aspirin and cancer prevention have a long and storied past.
"Aspirin is an anti-inflammatory agent. So by suppressing inflammation, you can reduce the risk," said Yang, who was not involved in the NCI analysis. http://www.stonybrookphysicians.com/doctor/YANG_MD_PHD_VINCENT_3825.asp
He added that while intriguing, the research is not strong enough to recommend aspirin as a preventive. Aspirin can cause side effects, especially gastrointestinal bleeding, Yang said.
Trabert and NCI colleague Dr. Nicolas Wentzensen conducted the type of study known as a meta-analysis. They re-examined previously published data.
From the 12 large studies they reviewed -- nine from the United States -- 8,000 women were involved.
Each participant took one of three types of medications: aspirin; other nonsteroidal anti-inflammatory drugs -- NSAIDs -- such as ibuprofen; or, acetaminophen, a pain reliever that doesn't reduce inflammation.
Aspirin takers had the highest risk reduction. For those who took non-aspirin NSAIDs, the outcome was less clear.
The scientists found only a 10 percent risk reduction among women who took an NSAID at least once per week. Acetaminophen, they said, was not associated with reduced ovarian cancer risk.
Dr. Michael Pearl, director of Stony Brook University Hospital's division of gynecological oncology, said as tantalizing as the study's results seem, he will not recommend aspirin as a preventive.
"When would you start recommending aspirin usage? Age 16 or when a woman is in her forties?" Pearl asked.
"This wasn't a prospective trial," Pearl said, referring to a randomized, placebo-controlled study, in which participants would take specific aspirin doses and results are compared with placebo takers.
Pearl defines ovarian cancer as the most lethal among gynecologic malignancies, its vague symptoms usually translating into late detection.
Trabert noted the study wasn't designed to influence clinical recommendations.
"Dosages [were] not uniform across participants," Trabert said of women who consumed varying aspirin doses. "We saw that participants who used aspirin daily . . . had a 20 percent lower risk of ovarian cancer compared to participants who did not use aspirin regularly."
Trabert's research, however, hails from a deepening well of scientific scholarship, which demonstrates that the pennies-per-dose drug has a powerful impact on cancer prevention.
Two weeks ago, scientists in Boston noted the risk of multiple myeloma -- a cancer involving blood-forming cells in the bone marrow -- also appears lower among aspirin takers.
Malignant melanoma, colorectal and breast cancers also may be lower among aspirin users, studies show.












Cold Spring Harb Symp Quant Biol. 2011;76:155-64. doi: 10.1101/sqb.2011.76.010819. Epub 2011 Nov 9.

Adenosine monophosphate-activated protein kinase: a central regulator of metabolism with roles in diabetes, cancer, and viral infection.

Hardie DG.

Author information

Abstract

Adenosine monophosphate-activated protein kinase (AMPK) is a cellular energy sensor activated by metabolic stresses that inhibit catabolic ATP production or accelerate ATP consumption. Once activated, AMPK switches on catabolic pathways, generating ATP, while inhibiting cell growth and proliferation, thus promoting energy homeostasis. AMPK is activated by the antidiabetic drug metformin, and by many natural products including "nutraceuticals" and compounds used in traditional medicines. Most of these xenobiotics activate AMPK by inhibiting mitochondrial ATP production. AMPK activation by metabolic stress requires the upstream kinase, LKB1, whose tumor suppressor effects may be largely mediated by AMPK. However, many tumor cells appear to have developed mechanisms to reduce AMPK activation and thus escape its growth-restraining effects. A similar phenomenon occurs during viral infection. If we can establish how down-regulation occurs in tumors and virus-infected cells, there may be therapeutic avenues to reverse these effects.
PMID:
22071265
[PubMed - indexed for MEDLINE]

Open Biol. 2013 Jan 8;3(1):120144. doi: 10.1098/rsob.120144.

Oxidants, antioxidants and the current incurability of metastatic cancers.

Watson J.

Author information

Abstract

The vast majority of all agents used to directly kill cancer cells (ionizing radiation, most chemotherapeutic agents and some targeted therapies) work through either directly or indirectly generating reactive oxygen species that block key steps in the cell cycle. As mesenchymal cancers evolve from their epithelial cell progenitors, they almost inevitably possess much-heightened amounts of antioxidants that effectively block otherwise highly effective oxidant therapies. Also key to better understanding is why and how the anti-diabetic drug metformin (the world's most prescribed pharmaceutical product) preferentially kills oxidant-deficient mesenchymal p53(- -) cells. A much faster timetable should be adopted towards developing more new drugs effective against p53(- -) cancers.
PMID:
23303309
[PubMed - indexed for MEDLINE]

PMCID:
PMC3603456

Free PMC Article
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)